Shots: This approval is based on P-I/II ‘205 study for the treatment of pediatric patients aged 1-17yr with Philadelphia chromosome-neg CD19 +ve (r/r) B-cell precursor ALL P-I/II ‘205 study (N=93) administering dose (5 ,15 μg/m2/day on days 1-7 day, 8-28 for cycle 1, followed by two weeks off, and 15 μg/m2/day on days 1-28 two weeks […]Read More
